Catherine Stehman-Breen

Catherine Stehman-Breen is a prominent leader in the biotechnology field, currently serving as the Chief Executive Officer of Chroma Medicine since December 2020. With extensive experience on various boards, Catherine is a member of the Board of Directors for Tenaya Therapeutics, Dyne Therapeutics, and Generation Bio. Previously, Catherine held significant roles such as Chief Research and Development Officer at Obsidian Therapeutics and Chief Medical Officer at Sarepta Therapeutics. Catherine's early career includes Vice President roles at Amgen and Regeneron, where responsibilities encompassed global development strategy and clinical execution. Academically, Catherine holds an MD from The University of Chicago Pritzker School of Medicine, a Master's Degree in Epidemiology from the University of Washington, and a Bachelor of Arts in Biology and Psychology from Colby College.